We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > S-Trimer

News List

First Participants Dosed in Adjuvanted S-Trimer COVID-19 Vaccine Candidate Trial americanpharmaceuticalreview
April 01, 2021
Clover Biopharmaceuticals and Dynavax Technologies announced the first participants have been dosed in Clover's SPECTRA trial (Study Evaluating Protective-Efficacy and Safety of Clover's Trimeric Recombinant Protein-based and Adjuvanted COVID-19 ...
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet prnasia
February 01, 2021
Clover Biopharmaceuticals today announced that the data from its Phase 1 clinical trial evaluating the safety and immunogenicity of its protein-based adjuvanted S-Trimer COVID-19 vaccine candidates was published in the peer-reviewed journal, The Lancet.
CEPI to fund Clover’s Covid-19 vaccine development pharmaceutical-technology
November 06, 2020
The Coalition for Epidemic Preparedness Innovations (CEPI) has extended its partnership to fund the development of Sichuan Clover Biopharmaceuticals’ protein-based S-Trimer Covid-19 vaccine candidate.